Chemed Co. (NYSE:CHE) EVP Sells $1,123,160.00 in Stock

Chemed Co. (NYSE:CHE) EVP Nicholas Michael Westfall sold 2,000 shares of the stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $561.58, for a total transaction of $1,123,160.00. Following the sale, the executive vice president now directly owns 5,990 shares in the company, valued at $3,363,864.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Chemed Stock Performance

NYSE:CHE opened at $590.56 on Friday. The company has a fifty day moving average of $544.09 and a two-hundred day moving average of $582.82. The stock has a market capitalization of $8.89 billion, a PE ratio of 31.67, a P/E/G ratio of 2.32 and a beta of 0.43. Chemed Co. has a fifty-two week low of $492.84 and a fifty-two week high of $654.62.

Chemed (NYSE:CHE) last posted its quarterly earnings data on Wednesday, July 24th. The company reported $5.47 earnings per share for the quarter, missing analysts’ consensus estimates of $5.59 by ($0.12). The company had revenue of $595.88 million for the quarter, compared to analyst estimates of $599.20 million. Chemed had a return on equity of 29.21% and a net margin of 12.88%. The business’s revenue was up 7.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $4.71 earnings per share. Research analysts forecast that Chemed Co. will post 21.77 earnings per share for the current year.

Chemed Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 18th. Shareholders of record on Thursday, May 30th were given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend was Thursday, May 30th. Chemed’s dividend payout ratio is presently 8.61%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. StockNews.com raised shares of Chemed from a “hold” rating to a “buy” rating in a report on Saturday, May 4th. Royal Bank of Canada lowered their price target on shares of Chemed from $712.00 to $697.00 and set an “outperform” rating on the stock in a report on Tuesday, May 21st.

Hedge Funds Weigh In On Chemed

A number of large investors have recently added to or reduced their stakes in CHE. Raymond James Financial Services Advisors Inc. raised its position in Chemed by 55.8% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 2,308 shares of the company’s stock worth $1,349,000 after acquiring an additional 827 shares during the period. Fenimore Asset Management Inc. raised its position in shares of Chemed by 0.4% in the fourth quarter. Fenimore Asset Management Inc. now owns 27,202 shares of the company’s stock valued at $15,906,000 after buying an additional 115 shares during the last quarter. DAVENPORT & Co LLC acquired a new stake in shares of Chemed in the fourth quarter valued at about $250,000. Trust Point Inc. acquired a new stake in shares of Chemed in the fourth quarter valued at about $2,325,000. Finally, International Assets Investment Management LLC acquired a new stake in shares of Chemed in the fourth quarter valued at about $430,970,000. 95.85% of the stock is currently owned by institutional investors and hedge funds.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.